PRN® Pharmacal Names Shigematsu Director of Marketing & Sales


(Pensacola, Fla. – May 28, 2015) – Corey Shigematsu recently joined PRN Pharmacal as Director of Marketing & Sales. Shigematsu will be responsible for planning and directing the marketing and sales of PRN Pharmacal-branded animal health products sold into the ethical veterinary market.

PRN Pharmacal Director of Marketing & Sales, Corey Shigematsu

PRN Pharmacal Director of Marketing & Sales, Corey Shigematsu

“We are thrilled to have Corey join our expanded management team. His prior pharma experience and his passion for the business will help us continue to meet the challenges and opportunities of a growing business and serve our customers well,” said Jeff Santosuosso, Vice President-General Manager.

Prior to joining PRN Pharmacal, Shigematsu was Associate Director of Marketing for Merck Animal Health where he served as marketing lead on the new product launch team and forecasting of long-range sales and production. Before becoming Associate Director of Marketing, Shigematsu was a Territory Representative in the Central Valley of California for Merck, responsible for the sales of companion animal products.

“I am tremendously happy about joining PRN Pharmacal. PRN has an incredible business culture, and we have an exciting future ahead of us filled with a number of opportunities for growth,” said Shigematsu.

Before joining Merck, Shigematsu served as a Human Pharma Specialty Sales Representative and Account Manager for Pfizer, Inc. He is also a FranklinCovey® certified speaker and trainer focusing on leadership and strategy. Shigematsu earned his Bachelor of Arts degree in Biology from The University of Southern California, Los Angeles, California.

Pegasus Laboratories manufactures products, which are distributed and marketed to the veterinary profession under the name PRN Pharmacal. Brand names include PROIN® for canine urinary incontinence and Collasate Silver® gel. To learn more about PRN Pharmacal products, visit or call 1-800-874-9764.


Leave A Reply